161 related articles for article (PubMed ID: 15646648)
1. Stratification of acute myeloid leukemia based on gene expression profiles.
Mano H
Int J Hematol; 2004 Dec; 80(5):389-94. PubMed ID: 15646648
[TBL] [Abstract][Full Text] [Related]
2. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.
Silva FP; Swagemakers SM; Erpelinck-Verschueren C; Wouters BJ; Delwel R; Vrieling H; van der Spek P; Valk PJ; Giphart-Gassler M
Blood; 2009 Oct; 114(14):3001-7. PubMed ID: 19666867
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
5. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
6. DNA microarray analysis of dysplastic morphology associated with acute myeloid leukemia.
Tsutsumi C; Ueda M; Miyazaki Y; Yamashita Y; Choi YL; Ota J; Kaneda R; Koinuma K; Fujiwara S; Kisanuki H; Ishikawa M; Ozawa K; Tomonaga M; Mano H
Exp Hematol; 2004 Sep; 32(9):828-35. PubMed ID: 15345284
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.
Dufour A; Schneider F; Metzeler KH; Hoster E; Schneider S; Zellmeier E; Benthaus T; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Hiddemann W; Bohlander SK; Spiekermann K
J Clin Oncol; 2010 Feb; 28(4):570-7. PubMed ID: 20038735
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
[TBL] [Abstract][Full Text] [Related]
9. Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
Haouas H; Haouas S; Uzan G; Hafsia A
Hematology; 2010 Aug; 15(4):193-203. PubMed ID: 20670477
[TBL] [Abstract][Full Text] [Related]
10. DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia.
Oshima Y; Ueda M; Yamashita Y; Choi YL; Ota J; Ueno S; Ohki R; Koinuma K; Wada T; Ozawa K; Fujimura A; Mano H
Leukemia; 2003 Oct; 17(10):1990-7. PubMed ID: 14513049
[TBL] [Abstract][Full Text] [Related]
11. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
[TBL] [Abstract][Full Text] [Related]
12. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
13. Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia.
Verhaak RG; Valk PJ
Cancer Treat Res; 2010; 145():67-83. PubMed ID: 20306246
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of serum MicroRNA-203 in patients with acute myeloid leukemia.
Guo Y
Bioengineered; 2019 Dec; 10(1):345-352. PubMed ID: 31411110
[TBL] [Abstract][Full Text] [Related]
15. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and regulation of an adenylyl cyclase network in acute myeloid leukemia.
Chen SL; Hu F; Wang DW; Qin ZY; Liang Y; Dai YJ
Aging (Albany NY); 2020 Jun; 12(12):11864-11877. PubMed ID: 32568101
[TBL] [Abstract][Full Text] [Related]
17. High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia.
de Jonge HJ; Valk PJ; Veeger NJ; ter Elst A; den Boer ML; Cloos J; de Haas V; van den Heuvel-Eibrink MM; Kaspers GJ; Zwaan CM; Kamps WA; Löwenberg B; de Bont ES
Blood; 2010 Sep; 116(10):1747-54. PubMed ID: 20522712
[TBL] [Abstract][Full Text] [Related]
18. Identification of genes with abnormal expression changes in acute myeloid leukemia.
Stirewalt DL; Meshinchi S; Kopecky KJ; Fan W; Pogosova-Agadjanyan EL; Engel JH; Cronk MR; Dorcy KS; McQuary AR; Hockenbery D; Wood B; Heimfeld S; Radich JP
Genes Chromosomes Cancer; 2008 Jan; 47(1):8-20. PubMed ID: 17910043
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Ang Q; Wang GJ; Zhu J; Wang WD
Oncotarget; 2016 Jan; 7(3):2585-95. PubMed ID: 26506237
[TBL] [Abstract][Full Text] [Related]
20. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
